Clinical trials: Melanoma of Skin
Advanced Solid Tumors, NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have…
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC
- Trial name
- NCT04157985
- Testing
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Dan Zandberg
Patients With Intransit Stage III/IV Melanoma
Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma
In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.
- Trial name
- NCT01213732
- Testing
- Isolated inferior limb perfusion
- Where
- 2 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Philogen S.p.A.
Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda® in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients…
- Trial name
- NCT07581509
- Testing
- Bmab1800, US-Licensed Keytruda
- Where
- Brazil
- Volunteers
- 138 people
- Sponsor
- Biocon Biologics UK PLC
Melanoma (Skin), Metastatic Cancer
S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic radiosurgery may kill more tumor cells.
- Trial name
- NCT00003911
- Testing
- stereotactic radiosurgery
- Where
- 86 sites in United States
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Malignant Melanoma
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
This is a randomized, open label study to investigate efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as first line treatment of adult patients with histologically confirmed unresectable…
- Trial name
- NCT04382664
- Testing
- UV1, Sargramostim, Ipilimumab
- Where
- 37 sites in United States, Belgium and 2 more
- Volunteers
- 156 people
- Sponsor
- Ultimovacs ASA
Melanoma
Post-Approval Study of MelaFind
The purpose of this study is to collect data to describe the real-world use and safety and effectiveness of MelaFind® in a post-approval clinical setting.
- Trial name
- NCT01700114
- Testing
- MelaFind
- Where
- 6 sites in United States
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Melanoma
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
This is a Phase I study combining vemurafenib and hydroxychloroquine in the treatment of BRAF V600E+ metastatic melanoma.
- Trial name
- NCT01897116
- Testing
- Hydroxychloroquine (HCQ), Vemurafenib (VEM)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma, Metastatic Melanoma
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
This phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor cobimetinib; or, (2) SOC plus bevacizumab, an anti-VEGF…
- Trial name
- NCT01495988
- Testing
- Vemurafenib, Bevacizumab, Cobimetinib
- Where
- 14 sites in United States
- Volunteers
- 10 people
- Sponsor
- Melanoma Research Foundation Breakthrough Consortium
Skin Neoplasms, Carcinoma, Basal Cell
Spanish Registry of Mohs Surgery
REGESMOHS (Registro Español de cirugía de Mohs) aims at describing effectiveness of Mohs surgery, and patient, tumor and technique factors related to adverse events and tumor recurrence.
- Conditions
- Skin Neoplasms, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Dermatofibrosarcoma
- Trial name
- REGESMOHS (NCT02310503)
- Testing
- Mohs surgery
- Where
- 15 sites in Spain
- Volunteers
- 6,000 people
- Sponsor
- Fundación Academia Española de Dermatología
Cancer, Malignant Melanoma
Efficacy Study of IL-21 to Treat Metastatic Melanoma
This trial is conducted in Oceania. A phase 2a study to assess the effect on tumor size. At least 14 to a maximum of 40 patients, who have not previously received treatment for their stage IV disease, will be treated for 6 weeks.
- Trial name
- NCT00336986
- Testing
- recombinant interleukin-21
- Where
- 7 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Novo Nordisk A/S
Melanoma
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Randomized trial to determine if neo-adjuvant subcutaneous GM-CSF restores the host regional lymph node immunity
- Trial name
- NCT02451488
- Testing
- GM-CSF, Standard of Care
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Melanoma
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
This research study is testing the "chemo-switch" strategy in melanoma, using biochemotherapy initially to shrink tumors and then switching to daily low-dose chemotherapy (temozolomide) together with sorafenib.
- Trial name
- NCT00673361
- Testing
- Concurrent decrescendo biochemotherapy regimen, Low-dose Temozolomide plus Sorafenib
- Volunteers
- 9 people
- Sponsor
- Duke University
Melanoma
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
- Trial name
- NCT01200342
- Testing
- Genasense, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
The trial is designed as a phase II evaluation of the effect of CY-503 on progression free survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy.
- Trial name
- NCT00658437
- Testing
- CY-503
- Where
- 4 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Cytavis Biopharma GmbH
Melanoma
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.
- Trial name
- NCT02155322
- Testing
- Pegylated Interferon Alfa-2b
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma (Skin)
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node…
- Trial name
- NCT00004196
- Testing
- recombinant interferon alfa, lymphangiography, Observation
- Where
- 4 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- University of Alabama at Birmingham
Melanoma and Sarcoma
TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)
This study will look at the safety and effects of combining a new drug called Talimogene Laherparepvec (T-VEC) with chemotherapy delivered by Isolated Limb Perfusion (ILP).
- Trial name
- TITAN (NCT03555032)
- Testing
- Talimogene laherparepvec (T-VEC)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer…
- Conditions
- Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770102)
- Testing
- Atezolizumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Breast Cancer, Ovarian Cancer
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- NCT05223218
- Testing
- Schirmer strip, a Class I Medical Device typically used to test for dry eye.
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Namida Lab
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.